Use of spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is usefule for preventing and/or treating multiple sclerosis

Abstract

The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.

1 . Use of a pharmaceutical composition comprising spironolactone, in any of its forms, polymorphs, hydrates, or solvates, together with pharmaceutically acceptable excipients, presenting an inhibitory action on the activation of T-lymphocytes, useful for preventing and/or treating multiple sclerosis. 
     
     
         2 . Use of a pharmaceutical composition according to  claim 1 , in the preparation of a medicine for oral administration, comprising spironolactone and pharmaceutically acceptable excipients for oral administration, destined to the treatment and/or prevention of multiple sclerosis. 
     
     
         3 . Use of a pharmaceutical composition according to  claim 2 , in the preparation of a medicine comprising spironolactonein the form of tablets, coated tablets, hard capsules, soft capsules, powder or other form of oral administration, in daily doses between 25 to 400 mg. 
     
     
         4 . Use of a pharmaceutical composition according to  claim 1 , in the preparation of a medicine comprising spironolactone for parenteral administration and destined to the treatment and/or prevention of multiple sclerosis, in daily doses between 25 to 400 mg. 
     
     
         5 . Use of a pharmaceutical composition according to  claim 4 , in the preparation of a medicine comprising spironolactone for parenteral administration in the form of an injectable solution or suspension and destined to the treatment and/or prevention of multiple sclerosis. 
     
     
         6 . Use of a pharmaceutical composition according to  claim 4 , in the preparation of a medicine for parenteral administration, including spironolactone, in the form of an implantable device destined to the treatment and/or prevention of multiple sclerosis, in a daily dose between 25 to 400 mg. 
     
     
         7 . Use of a pharmaceutical composition according to  claim 1 , for ex vivo treatment and further re-injection, with spironolactone in concentrations from 2 to 10 ug/ml, of T-cells and dendritic cells, obtained from peripheral blood of a patient suffering multiple sclerosis.